Skip to content
The Policy VaultThe Policy Vault

Oxytrol (prescription)Medical Mutual

overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency

Preferred products

  • Fesoterodine extended-release tablets
  • Myrbetriq (tablets, granules)
  • oxybutynin immediate-release tablets
  • oxybutynin immediate-release syrup
  • oxybutynin extended-release tablets
  • tolterodine tartrate immediate-release tablets
  • trospium chloride immediate-release tablets

Initial criteria

  • If the patient has tried a preferred agent, then authorization for a non-preferred agent may be given.
  • If the patient is age < 3 years, approve solifenacin.

Reauthorization criteria

  • If the patient continues therapy with the requested non-preferred agent after being stable for at least 90 days [verification in prescription claims history required] or, if not available, [verification by prescribing physician required] AND meets ONE of the following:
  • 1. The patient has at least 130 days of prescription claims history on file and claims history supports that the patient has received the requested non-preferred agent for 90 days within a 130-day look-back period AND there is no generic equivalent available for the requested nonpreferred product (i.e. AA-rated or AB-rated to the requested nonpreferred product); OR
  • 2. When 130 days of the patient’s prescription claims history file is unavailable for verification, the prescriber must verify that the patient has been receiving the requested non-preferred agent for 90 days AND that the patient has been receiving the requested non-preferred agent via paid claims (i.e. the patient has NOT been receiving samples or coupons or other types of waivers in order to obtain access to the requested non-preferred agent) AND there is no generic equivalent available for the requested nonpreferred product (i.e. AA-rated or AB-rated to the requested nonpreferred product).

Approval duration

1 year